Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients

Arthritis Research and Therapy

Volumn 16, Issue 2, 2014, Pages

  Günther, Jeannine ^a,b   Kill, Angela ^a,b   Becker, Mike O ^a   Heidecke, Harald ^c   Rademacher, Judith ^a,b   Siegert, Elise ^a   Radić, Mislav ^a,d   Burmester, Gerd Rüdiger ^a   Dragun, Duska ^a   Riemekasten, Gabriela ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

^c CellTrend GmbH   (Germany)

^d UNIVERSITY HOSPITAL SPLIT   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; AUTOANTIBODY; CCL18 CHEMOKINE; CELL SURFACE MARKER; CHEMOKINE; ENDOTHELIN A RECEPTOR; IMMUNOGLOBULIN G; INTERLEUKIN 8; UNCLASSIFIED DRUG; CHEMOKINE CCL18; MESSENGER RNA; AUTOANTIBODIES; CCL18 PROTEIN, HUMAN; CHEMOKINES, CC; INTERLEUKIN-18; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ENDOTHELIN A;

ADULT; ARTICLE; B LYMPHOCYTE; CD3+ T LYMPHOCYTE; CELL ISOLATION; CELL MOTILITY; CELL STIMULATION; CHEMOTAXIS ASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IN VITRO STUDY; LUNG DIFFUSION CAPACITY; LUNG FIBROSIS; LYMPHOCYTE MIGRATION; MALE; MIDDLE AGED; MRNA EXPRESSION ASSAY; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; REAL TIME POLYMERASE CHAIN REACTION; SYSTEMIC SCLEROSIS; T CELL CULTURE; CELL MIGRATION; MONOCYTE; T LYMPHOCYTE; BIOSYNTHESIS; CELL MOVEMENT; CHEMOTAXIS, LEUKOCYTE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOLOGY; METABOLISM; MONOCYTES; REAL-TIME POLYMERASE CHAIN REACTION; SCLERODERMA, SYSTEMIC;

ADULT; AUTOANTIBODIES; CELL MOVEMENT; CHEMOKINES, CC; CHEMOTAXIS, LEUKOCYTE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-18; MALE; MIDDLE AGED; MONOCYTES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ENDOTHELIN A; SCLERODERMA, SYSTEMIC;

EID: 84900804616     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4503     Document Type: Article

References (65)

1. Sakkas LI, Chikanza IC, Platsoucas CD. Mechanisms of disease: the role of immune cells in the pathogenesis of systemic sclerosis. Nat Clin Pract Rheumatol 2006, 2:679-685.
2. Riemekasten G, Philippe A, Näther M, Slowinski T, Müller DN, Heidecke H, Matucci-Cerinic M, Czirják L, Lukitsch I, Becker M, Kill A, van Laar JM, Catar R, Luft FC, Burmester GR, Hegner B, Dragun D. Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis 2011, 70:530-536. 10.1136/ard.2010.135772, 21081526.
3. Sakkas LI, Platsoucas CD. Is systemic sclerosis an antigen-driven T cell disease?. Arthritis Rheum 2004, 50:1721-1733. 10.1002/art.20315, 15188347.
4. Abraham DJ, Varga J. Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol 2005, 26:587-595. 10.1016/j.it.2005.09.004, 16168711.
5. Prescott RJ, Freemont AJ, Jones CJ, Hoyland J, Fielding P. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 1992, 166:255-263. 10.1002/path.1711660307, 1517881.
6. Trojanowska M. Cellular and molecular aspects of vascular dysfunction in systemic sclerosis. Nat Rev Rheumatol 2010, 6:453-460. 10.1038/nrrheum.2010.102, 3824624, 20585340.
7. Nataraj C, Oliverio MI, Mannon RB, Mannon PJ, Audoly LP, Amuchastegui CS, Ruiz P, Smithies O, Coffman TM. Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway. J Clin Invest 1999, 104:1693-1701. 10.1172/JCI7451, 409880, 10606623.
8. Jurewicz M, McDermott DH, Sechler JM, Tinckam K, Takakura A, Carpenter CB, Milford E, Abdi R. Human T and natural killer cells possess a functional renin-angiotensin system: further mechanisms of angiotensin II-induced inflammation. J Am Soc Nephrol 2007, 18:1093-1102. 10.1681/ASN.2006070707, 17329576.
9. Marchesi C, Paradis P, Schiffrin EL. Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol Sci 2008, 29:367-374. 10.1016/j.tips.2008.05.003, 18579222.
10. Brassard P, Amiri F, Schiffrin EL. Combined angiotensin II type 1 and type 2 receptor blockade on vascular remodeling and matrix metalloproteinases in resistance arteries. Hypertension 2005, 46:598-606. 10.1161/01.HYP.0000176744.15592.7d, 16043661.
11. Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J. Inflammation and angiotensin II. Int J Biochem Cell Biol 2003, 35:881-900. 10.1016/S1357-2725(02)00271-6, 12676174.
12. Frommer KW, Müller-Ladner U. Expression and function of ETA and ETB receptors in SSc. Rheumatology (Oxford) 2008, 47:v27-v28. 10.1093/rheumatology/ken274, 18784135.
13. Schiffrin EL. Vascular endothelin in hypertension. Vascul Pharmacol 2005, 43:19-29. 10.1016/j.vph.2005.03.004, 15955745.
14. Bellisai F, Morozzi G, Scaccia F, Chellini F, Simpatico A, Pecetti G, Galeazzi M. Evaluation of the effect of bosentan treatment on proinflammatory cytokine serum levels in patients affected by systemic sclerosis. Int J Immunopathol Pharmacol 2011, 24:261-264.
15. Kawaguchi Y, Takagi K, Hara M, Fukasawa C, Sugiura T, Nishimagi E, Harigai M, Kamatani N. Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors. Arthritis Rheum 2004, 50:216-226. 10.1002/art.11364, 14730619.
16. Rasini E, Cosentino M, Marino F, Legnaro M, Ferrari M, Guasti L, Venco A, Lecchini S. Angiotensin II type 1 receptor expression on human leukocyte subsets: a flow cytometric and RT-PCR study. Regul Pept 2006, 134:69-74. 10.1016/j.regpep.2006.01.007, 16530863.
17. Hoch NE, Guzik TJ, Chen W, Deans T, Maalouf SA, Gratze P, Weyand C, Harrison DG. Regulation of T-cell function by endogenously produced angiotensin II. Am J Physiol Regul Integr Comp Physiol 2009, 296:R208-R216. 2643984, 19073907.
18. Kintscher U, Wakino S, Kim S, Fleck E, Hsueh WA, Law RE. Angiotensin II induces migration and Pyk2/paxillin phosphorylation of human monocytes. Hypertension 2001, 37:587-593. 10.1161/01.HYP.37.2.587, 11230339.
19. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980, 23:581-590. 10.1002/art.1780230510, 7378088, Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.
20. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, Rowell N, Wollheim F. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988, 15:202-205.
21. Walker UA, Tyndall A, Czirják L, Denton C, Farge-Bancel D, Kowal-Bielecka O, Müller-Ladner U, Bocelli-Tyndall C, Matucci-Cerinic M. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 2007, 66:754-763. 10.1136/ard.2006.062901, 1954657, 17234652.
22. Mayes MD, Trojanowska M. Genetic factors in systemic sclerosis. Arthritis Res Ther 2007, 9:S5.
23. Herrera M, Sparks MA, Alfonso-Pecchio AR, Harrison-Bernard LM, Coffman TM. Lack of specificity of commercial antibodies leads to misidentification of angiotensin type 1 receptor protein. Hypertension 2013, 61:253-258. 10.1161/HYPERTENSIONAHA.112.203679, 3523722, 23150519.
24. Abraham DJ, Vancheeswaran R, Dashwood MR, Rajkumar VS, Pantelides P, Xu SW, du Bois RM, Black CM. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol 1997, 151:831-841. 1857854, 9284832.
25. Nickenig G. Central role of the AT1-receptor in atherosclerosis. J Hum Hypertens 2002, 16:S26-S33.
26. Trojanowska M, Varga J. Molecular pathways as novel therapeutic targets in systemic sclerosis. Curr Opin Rheumatol 2007, 19:568-573. 10.1097/BOR.0b013e3282e6f495, 17917537.
27. Ouali R, Berthelon MC, Bégeot M, Saez JM. Angiotensin II receptor subtypes AT1 and AT2 are down-regulated by angiotensin II through AT1 receptor by different mechanisms. Endocrinology 1997, 138:725-733.
28. Mayes MD. Endothelin and endothelin receptor antagonists in systemic rheumatic disease. Arthritis Rheum 2003, 48:1190-1199. 10.1002/art.10895, 12746891.
29. Williams JT, Ingram SL, Henderson G, Chavkin C, von Zastrow M, Schulz S, Koch T, Evans CJ, Christie MJ. Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol Rev 2013, 65:223-254. 10.1124/pr.112.005942, 3565916, 23321159.
30. Rajagopal S, Rajagopal K, Lefkowitz RJ. Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat Rev Drug Discov 2010, 9:373-386. 10.1038/nrd3024, 2902265, 20431569.
31. Dimitrijevic I, Rissler P, Luts L, Edvinsson L. Reduced expression of angiotensin II and angiotensin receptor type 1 and type 2 in resistance arteries from nasal lesions in granulomatosis with polyangiitis (Wegener's granulomatosis). Scand J Rheumatol 2011, 40:448-452. 10.3109/03009742.2011.593545, 21936613.
32. Silva-Filho JL, Souza MC, Henriques M, Morrot A, Savino W, Nunes MP, Caruso-Neves C, Pinheiro AA. AT1 receptor-mediated angiotensin II activation and chemotaxis of T lymphocytes. Mol Immunol 2011, 48:1835-1843. 10.1016/j.molimm.2011.05.008, 21641648.
33. Xu SW, Denton CP, Dashwood MR, Abraham DJ, Black CM. Endothelin-1 regulation of intercellular adhesion molecule-1 expression in normal and sclerodermal fibroblasts. J Cardiovasc Pharmacol 1998, 31:S545-S547.
34. Dragun D, Müller DN, Bräsen JH, Fritsche L, Nieminen-Kelhä M, Dechend R, Kintscher U, Rudolph B, Hoebeke J, Eckert D, Mazak I, Plehm R, Schönemann C, Unger T, Budde K, Neumayer HH, Luft FC, Wallukat G. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005, 352:558-569. 10.1056/NEJMoa035717, 15703421.
35. Okruhlicova L, Morwinski R, Schulze W, Bartel S, Weismann P, Tribulova N, Wallukat G. Autoantibodies against G-protein-coupled receptors modulate heart mast cells. Cell Mol Immunol 2007, 4:127-133.
36. Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, Jüpner A, Baur E, Nissen E, Vetter K, Neichel D, Dudenhausen JW, Haller H, Luft FC. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest 1999, 103:945-952. 10.1172/JCI4106, 408252, 10194466.
37. Xia Y, Wen H, Bobst S, Day MC, Kellems RE. Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human trophoblast cells. J Soc Gynecol Investig 2003, 10:82-93. 10.1016/S1071-5576(02)00259-9, 12593997.
38. Zhou CC, Ahmad S, Mi T, Abbasi S, Xia L, Day MC, Ramin SM, Ahmed A, Kellems RE, Xia Y. Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated T-cells signaling. Hypertension 2008, 51:1010-1019. 10.1161/HYPERTENSIONAHA.107.097790, 3261612, 18259044.
39. Xia Y, Kellems RE. Is preeclampsia an autoimmune disease?. Clin Immunol 2009, 133:1-12. 10.1016/j.clim.2009.05.004, 3380609, 19501024.
40. Dechend R, Gratze P, Wallukat G, Shagdarsuren E, Plehm R, Bräsen JH, Fiebeler A, Schneider W, Caluwaerts S, Vercruysse L, Pijnenborg R, Luft FC, Müller DN. Agonistic autoantibodies to the AT1 receptor in a transgenic rat model of preeclampsia. Hypertension 2005, 45:742-746. 10.1161/01.HYP.0000154785.50570.63, 15699466.
41. Dechend R, Homuth V, Wallukat G, Kreuzer J, Park JK, Theuer J, Juepner A, Gulba DC, Mackman N, Haller H, Luft FC. AT( 1 ) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor. Circulation 2000, 101:2382-2387. 10.1161/01.CIR.101.20.2382, 10821814.
42. Dechend R, Viedt C, Müller DN, Ugele B, Brandes RP, Wallukat G, Park JK, Janke J, Barta P, Theuer J, Fiebeler A, Homuth V, Dietz R, Haller H, Kreuzer J, Luft FC. AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. Circulation 2003, 107:1632-1639. 10.1161/01.CIR.0000058200.90059.B1, 12668498.
43. Bobst SM, Day MC, Gilstrap LC, Xia Y, Kellems RE. Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human mesangial cells and induce interleukin-6 and plasminogen activator inhibitor-1 secretion. Am J Hypertens 2005, 18:330-336. 10.1016/j.amjhyper.2004.10.002, 15797649.
44. Walther T, Wallukat G, Jank A, Bartel S, Schultheiss HP, Faber R, Stepan H. Angiotensin II type 1 receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature. Hypertension 2005, 46:1275-1279. 10.1161/01.HYP.0000190040.66563.04, 16260641.
45. Hiemann NE, Meyer R, Wellnhofer E, Schoenemann C, Heidecke H, Lachmann N, Hetzer R, Dragun D. Non-HLA antibodies targeting vascular receptors enhance alloimmune response and microvasculopathy after heart transplantation. Transplantation 2012, 94:919-924.
46. Mateo T, Abu Nabah YN, Abu Taha M, Mata M, Cerdá-Nicolás M, Proudfoot AEI, Stahl RAK, Issekutz AC, Cortijo J, Morcillo EJ, Jose PJ, Sanz MJ. Angiotensin II-induced mononuclear leukocyte interactions with arteriolar and venular endothelium are mediated by the release of different CC chemokines. J Immunol 2006, 176:5577-5586. 10.4049/jimmunol.176.9.5577, 16622027.
47. Savoia C, Schiffrin EL. Inflammation in hypertension. Curr Opin Nephrol Hypertens 2006, 15:152-158.
48. Brasier AR, Jamaluddin M, Han Y, Patterson C, Runge MS. Angiotensin II induces gene transcription through cell-type-dependent effects on the nuclear factor-κB (NF-κB) transcription factor. Mol Cell Biochem 2000, 212:155-169. 10.1023/A:1007133710837, 11108147.
49. Nabah YN, Mateo T, Estellés R, Mata M, Zagorski J, Sarau H, Cortijo J, Morcillo EJ, Jose PJ, Sanz MJ. Angiotensin II induces neutrophil accumulation in vivo through generation and release of CXC chemokines. Circulation 2004, 110:3581-3586. 10.1161/01.CIR.0000148824.93600.F3, 15569833.
50. Schmidt-Ott KM, Kagiyama S, Phillips MI. The multiple actions of angiotensin II in atherosclerosis. Regul Pept 2000, 93:65-77. 10.1016/S0167-0115(00)00178-6, 11033054.
51. Muller DN, Mervaala EM, Schmidt F, Park JK, Dechend R, Genersch E, Breu V, Löffler BM, Ganten D, Schneider W, Haller H, Luft FC. Effect of bosentan on NF-κB, inflammation, and tissue factor in angiotensin II-induced end-organ damage. Hypertension 2000, 36:282-290. 10.1161/01.HYP.36.2.282, 10948091.
52. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007, 117:557-567. 10.1172/JCI31139, 1804347, 17332883.
53. De Palma R, D'Aiuto E, Vettori S, Cuoppolo P, Abbate G, Valentini G. Peripheral T cells from patients with early systemic sclerosis kill autologous fibroblasts in co-culture: Is T-cell response aimed to play a protective role?. Rheumatology (Oxford) 2010, 49:1257-1266. 10.1093/rheumatology/keq094, 20418226.
54. Prasse A, Pechkovsky DV, Toews GB, Schäfer M, Eggeling S, Ludwig C, Germann M, Kollert F, Zissel G, Müller-Quernheim J. CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis. Arthritis Rheum 2007, 56:1685-1693. 10.1002/art.22559, 17469163.
55. Schutyser E, Richmond A, Van Damme J. Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes. J Leukoc Biol 2005, 78:14-26. 10.1189/jlb.1204712, 2665283, 15784687.
56. Mathai SK, Gulati M, Peng X, Russell TR, Shaw AC, Rubinowitz AN, Murray LA, Siner JM, Antin-Ozerkis DE, Montgomery RR, Reilkoff RA, Bucala RJ, Herzog EL. Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype. Lab Invest 2010, 90:812-823. 10.1038/labinvest.2010.73, 3682419, 20404807.
57. Prasse A, Pechkovsky DV, Toews GB, Jungraithmayr W, Kollert F, Goldmann T, Vollmer E, Müller-Quernheim J, Zissel G. A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am J Respir Crit Care Med 2006, 173:781-792. 10.1164/rccm.200509-1518OC, 16415274.
58. Luzina IG, Tsymbalyuk N, Choi J, Hasday JD, Atamas SP. CCL18-stimulated upregulation of collagen production in lung fibroblasts requires Sp1 signaling and basal Smad3 activity. J Cell Physiol 2006, 206:221-228. 10.1002/jcp.20452, 16021625.
59. Rodríguez-Vita J, Sánchez-López E, Esteban V, Rupérez M, Egido J, Ruiz-Ortega M. Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-β-independent mechanism. Circulation 2005, 111:2509-2517. 10.1161/01.CIR.0000165133.84978.E2, 15883213.
60. Wang W, Huang XR, Canlas E, Oka K, Truong LD, Deng C, Bhowmick NA, Ju W, Bottinger EP, Lan HY. Essential role of Smad3 in angiotensin II-induced vascular fibrosis. Circ Res 2006, 98:1032-1039. 10.1161/01.RES.0000218782.52610.dc, 1450325, 16556868.
61. Koch AE, Kronfeld-Harrington LB, Szekanecz Z, Cho MM, Haines GK, Harlow LA, Strieter RM, Kunkel SL, Massa MC, Barr WG, Jimenez SA. In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis: their role in early and late disease. Pathobiology 1993, 61:239-246. 10.1159/000163802, 7507681.
62. Suwannalai P, van de Stadt LA, Radner H, Steiner G, El-Gabalawy HS, Zijde CM, van Tol MJ, van Schaardenburg D, Huizinga TW, Toes RE, Rouw LA. Avidity maturation of anti-citrullinated protein antibodies in rheumatoid arthritis. Arthritis Rheum 2012, 64:1323-1328. 10.1002/art.33489, 22130974.
63. Schmidt K, Martinez-Gamboa L, Meier S, Witt C, Meisel C, Hanitsch LG, Becker MO, Huscher D, Burmester GR, Riemekasten G. Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients. Arthritis Res Ther 2009, 11:R111. 10.1186/ar2766, 2745793, 19615053.
64. Kodera M, Hasegawa M, Komura K, Yanaba K, Takehara K, Sato S. Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis. Arthritis Rheum 2005, 52:2889-2896. 10.1002/art.21257, 16142750.
65. Prasse A, Müller-Quernheim J. Non-invasive biomarkers in pulmonary fibrosis. Respirology 2009, 14:788-795. 10.1111/j.1440-1843.2009.01600.x, 19703061.